ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 954,19
0,02%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Marker Therapeutics (delisted) (TPIV)

  7. Marker Therapeutics (delisted) (TPIV) Actualités

TPIV

TapImmune, Inc. (TPIV)

Marker Therapeutics (delisted)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TPIV
DateHeureSourceTitreSymboleSociété
19/10/201823h10Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:TPIVMarker Therapeutics (delisted)
19/10/201822h55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TPIVMarker Therapeutics (delisted)
19/10/201822h34Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TPIVMarker Therapeutics (delisted)
17/10/201822h02Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:TPIVMarker Therapeutics (delisted)
17/10/201822h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TPIVMarker Therapeutics (delisted)
17/10/201817h45PR Newswire (US)TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And FinancingNASDAQ:TPIVMarker Therapeutics (delisted)
10/10/201812h30PR Newswire (US)TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded b...NASDAQ:TPIVMarker Therapeutics (delisted)
25/09/201814h05PR Newswire (US)TapImmune to Present at Two Upcoming Investor ConferencesNASDAQ:TPIVMarker Therapeutics (delisted)
14/09/201820h56Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:TPIVMarker Therapeutics (delisted)
12/09/201814h05PR Newswire (US)TapImmune To Present at 2018 Janney Healthcare ConferenceNASDAQ:TPIVMarker Therapeutics (delisted)
07/09/201823h40Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:TPIVMarker Therapeutics (delisted)
29/08/201812h30PR Newswire (US)TapImmune to Participate at Two Upcoming Industry ConferencesNASDAQ:TPIVMarker Therapeutics (delisted)
09/08/201823h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TPIVMarker Therapeutics (delisted)
08/08/201822h42Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TPIVMarker Therapeutics (delisted)
13/07/201823h20Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:TPIVMarker Therapeutics (delisted)
21/06/201818h33Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(7) (424b7)NASDAQ:TPIVMarker Therapeutics (delisted)
08/06/201815h15PR Newswire (US)TapImmune Announces Pricing of $70 Million Private PlacementNASDAQ:TPIVMarker Therapeutics (delisted)
31/05/201812h30PR Newswire (US)TapImmune to Present at the Jefferies 2018 Global Healthcare ConferenceNASDAQ:TPIVMarker Therapeutics (delisted)
30/05/201812h30PR Newswire (US)TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment ForumNASDAQ:TPIVMarker Therapeutics (delisted)
24/05/201822h05Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:TPIVMarker Therapeutics (delisted)
23/05/201812h30PR Newswire (US)TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transfor...NASDAQ:TPIVMarker Therapeutics (delisted)
22/05/201812h30PR Newswire (US)TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, ...NASDAQ:TPIVMarker Therapeutics (delisted)
16/05/201823h15Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:TPIVMarker Therapeutics (delisted)
16/05/201812h30PR Newswire (US)TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy PlatformNASDAQ:TPIVMarker Therapeutics (delisted)
15/05/201822h05PR Newswire (US)TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker TherapeuticsNASDAQ:TPIVMarker Therapeutics (delisted)
15/05/201811h32PR Newswire (US)TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology PlatformNASDAQ:TPIVMarker Therapeutics (delisted)
07/05/201812h30PR Newswire (US)TapImmune to Present at 2018 NYC Oncology Investor ConferenceNASDAQ:TPIVMarker Therapeutics (delisted)
01/05/201812h30PR Newswire (US)TapImmune to Present at 2018 Disruptive Growth & Healthcare ConferenceNASDAQ:TPIVMarker Therapeutics (delisted)
05/04/201822h05PR Newswire (US)TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical UpdateNASDAQ:TPIVMarker Therapeutics (delisted)
29/03/201812h30PR Newswire (US)TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and WebcastNASDAQ:TPIVMarker Therapeutics (delisted)
 Showing the most relevant articles for your search:NASDAQ:TPIV

Dernières Valeurs Consultées

TSX
FMAX
Hamilton US Financials Y...
BOV
INBR32M
Inter &
TSXV
SYZ
Sylogist
TG
MGM
Capricorn Metals
LSE
FPEB
F&c Private Equity Trust
NASDAQ
BNTX
BioNTech
BIT
F15272
Vontobel Financial Produ...
COIN
BIDXUSD
ASX
GSBU33
Commonwealth of Australia
BOV
BIEI39M
BlackRock Institutional ...
COIN
KAPETH
Kapital DAO Token
USOTC
DFKCY
Daifuku (PK)
COIN
ZLPUSD
TSXV
BAL.H@OL
EU
IGOVA
SPDR GOVA INAV
LSE
USDC
Lg Esg Usd
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés